Protein kinase CK2 accumulation in "oncophilic" cells: Causes and effects

Molecular and Cellular Biochemistry

Volumn 356, Issue 1-2, 2011, Pages 5-10

  Ruzzene, Maria ^a,b   Tosoni, Kendra ^a,b   Zanin, Sofia ^a   Cesaro, Luca ^a   Pinna, Lorenzo A ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Addiction; Apoptosis; Cancer cells; Chaperone proteins; CK2; Multidrug resistance

Indexed keywords

CASEIN KINASE II; CELL CYCLE PROTEIN 37; HEAT SHOCK PROTEIN 90; STAUROSPORINE;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEGRADATION; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; MUTANT; NEOPLASM; NONHUMAN; ONCOGENE;

CASEIN KINASE II; HUMANS; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; NEOPLASMS; PHOSPHOPROTEINS; PROTEIN STABILITY; PROTEOME;

EID: 84855238928     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0959-2     Document Type: Article

References (20)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912-1934 (Pubitemid 35425239)
2. Salvi M, Cesaro L, Pinna LA (2010) Variable contribution of protein kinases to the generation of the human phosphoproteome: a global weblogo analysis. BioMol Concepts 1:185-195
3. Dobrowolska G, Lozeman FJ, Li D, Krebs EG (1999) CK2, a protein kinase of the next millennium. Mol Cell Biochem 191:3-12 (Pubitemid 29092704)
4. Sarno S, Ghisellini P, Pinna LA (2002) Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme. J Biol Chem 277:22509-22514 (Pubitemid 34967224)
5. Niefind K, Raaf J, Issinger OG (2009) Protein kinase CK2 in health and disease: protein kinase CK2: from structures to insights. Cell Mol Life Sci 66:1800-1816
6. Ruzzene M, Di Maira G, Tosoni K, Pinna LA (2010) Assessment of CK2 constitutive activity in cancer cells. Methods Enzymol 484:495-514
7. Hung MS, Lin YC, Mao JH, Kim IJ, Xu Z, Yang CT, Jablons DM, You L (2010) Functional polymorphism of the CK2alpha intron less gene plays oncogenic roles in lung cancer. PLoS One 5:e11418
8. Ruzzene M, Pinna LA (2010) Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 1804:499-504
9. Solimini NL, Luo J, Elledge SJ (2007) Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130:986-988 (Pubitemid 47422308)
10. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G, Di Maira G, Barbon F, Cabrelle A, Zambello R, Adami F, Trentin L, Pinna LA, Semenzato G (2006) Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108:1698-1707 (Pubitemid 44316140)
11. Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI, Min YH (2007) Protein kinase CK2α as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 13:1019-1028
12. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata JT (2008) PTEN posttranslational inactivation and hyperactivation of the PI3K/ Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118:3762-3774
13. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70:10288-10298
14. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K (2001) Protein kinase CK2 signal in neoplasia. Histol Histopathol 16:573-582 (Pubitemid 32297655)
15. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA, Ruzzene M (2007) Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 26:6915-6926 (Pubitemid 47609076)
16. Miyata Y (2009) Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. Cell Mol Life Sci 66:1840-1849
17. Di Maira G, Brustolon F, Tosoni K, Belli S, Krämer SD, Pinna LA, Ruzzene M (2008) Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis. Mol Cell Biochem 316:155-161
18. Ruzzene M, Penzo D, Pinna LA (2002) Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364:41-47 (Pubitemid 34538944)
19. Uehara Y (2003) Natural product origins of Hsp90 inhibitors. Curr Cancer Drug Targets 3:325-330 (Pubitemid 37128318)
20. Zhang H, Neely L, Lundgren K, Yang YC, Lough R, Timple N, Burrows F (2010) BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer 126:1226-1234